drugset / Trial / NCT02019355

Actinic Keratosis Study

NCT02019355

Phase 0 Completed 132 enrolled Washington University School of Medicine
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.

Timeline

Start
2013-10
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 % Topical
Background fluorouracil Small molecule 5 % Topical

Indications